Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,039,001
  • Shares Outstanding, K 58,592
  • Annual Sales, $ 54,030 K
  • Annual Income, $ -412,780 K
  • EBIT $ -472 M
  • EBITDA $ -474 M
  • 60-Month Beta 0.79
  • Price/Sales 38.17
  • Price/Cash Flow N/A
  • Price/Book 1.72

Options Overview Details

View History
  • Implied Volatility 56.51% (+1.74%)
  • Historical Volatility 47.81%
  • IV Percentile 28%
  • IV Rank 8.30%
  • IV High 254.54% on 11/18/25
  • IV Low 38.58% on 05/21/25
  • Expected Move (DTE 10) 2.46 (7.00%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 40
  • Volume Avg (30-Day) 355
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 43,405
  • Open Int (30-Day) 43,774
  • Expected Range 32.65 to 37.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.82
  • Number of Estimates 6
  • High Estimate $-1.76
  • Low Estimate $-1.87
  • Prior Year $-1.55
  • Growth Rate Est. (year over year) -17.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.00 +30.04%
on 03/12/26
36.35 -3.41%
on 03/31/26
+7.64 (+27.81%)
since 03/06/26
3-Month
26.04 +34.83%
on 02/09/26
36.35 -3.41%
on 03/31/26
+6.57 (+23.02%)
since 01/07/26
52-Week
22.24 +57.87%
on 11/19/25
46.00 -23.67%
on 11/18/25
+9.21 (+35.56%)
since 04/07/25

Most Recent Stories

More News
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 35.11 (+0.89%)
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

NEW YORK , April 1, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO) concerning...

AGIO : 35.11 (+0.89%)
AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money

NEW YORK , March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.:

AGIO : 35.11 (+0.89%)
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway  Company plans to submit mitapivat sNDA in sickle cell disease in the coming...

AGIO : 35.11 (+0.89%)
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation

NEW YORK , March 25, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO)...

AGIO : 35.11 (+0.89%)
ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK , March 18, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO)...

AGIO : 35.11 (+0.89%)
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation

NEW YORK , March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.:

AGIO : 35.11 (+0.89%)
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK , March 11, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO)...

AGIO : 35.11 (+0.89%)
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO

NEW YORK , March 10, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.:

AGIO : 35.11 (+0.89%)
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO

NEW YORK , March 4, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO)...

AGIO : 35.11 (+0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 36.29
2nd Resistance Point 35.80
1st Resistance Point 35.46
Last Price 35.11
1st Support Level 34.62
2nd Support Level 34.13
3rd Support Level 33.78

See More

52-Week High 46.00
Fibonacci 61.8% 36.92
Last Price 35.11
Fibonacci 50% 34.12
Fibonacci 38.2% 31.32
52-Week Low 22.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.